23999-16-8

Basic information

• Product Name: 3-(diethylamino)-N-(4-nitrophenyl)propanamide
• Synonyms: 3-(diethylamino)-N-(4-nitrophenyl)propanamide
• CAS NO: 23999-16-8
• Molecular Weight: 265.312
• Mol File: 23999-16-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-(diethylamino)-N-(4-nitrophenyl)propanamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(diethylamino)-N-(4-nitrophenyl)propanamide(23999-16-8)
• EPA Substance Registry System: 3-(diethylamino)-N-(4-nitrophenyl)propanamide(23999-16-8)

Safety Data

• Hazardous Substances Data: 23999-16-8(Hazardous Substances Data)

Upstream product

• 100-01-6 4-nitro-aniline 
• 109-89-7 diethylamine 
• 625-36-5 2-chloropropionyl chloride 
• 19313-88-3 3-chloro-N-(4-nitrophenyl)propanamide 

Downstream Products

• 1262546-36-0 N-(4-azidophenyl)-3-(diethylamino)propanamide 
• 1622093-59-7 N-(4-(4-((4-(1H-phenanthro[9,10-d]imidazol-2-yl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl)-3-(diethylamino)propanamide 
• 23043-12-1 N-(4-aminophenyl)-3-(diethylamino)propanamide 
• 1446421-00-6 N-(4-(3-(4-(bis(2-chloroethyl)amino)phenyl)ureido)phenyl)-3-(diethylamino)propanamide 

Relevant articles and documents

Design and synthesis of potent antitumor water-soluble phenyl N-mustard-benzenealkylamide conjugates via a bioisostere approach

A series of new, water-soluble phenyl N-mustard-benzenealkylamide conjugates containing hydrophilic ω-dialkylaminoalkylamide or ω-cyclic aminoalkylamide moieties were synthesized via a bioisostere approach. These compounds have a broad spectrum of antitumor activity against a panel of human tumor cell lines. Of these derivatives, compound 18b effectively suppressed the growth of colon cancer (HCT-116), prostate cancer (PC3), and lung cancer (H460) xenografts. The growth of HCT-116 xenografts was almost completely suppressed when co-treated with compound 18b and 5-fluorouracil. Furthermore, compound 18b can induce DNA cross-linking and cell-cycle arrest at the G2/M phase. Early preclinical studies, including pharmacokinetics in rats, inhibition of the hERG, and 14 days of acute intravenous injection toxicity, suggest that compound 18b is a promising candidate for further preclinical studies.

A novel series of G-quadruplex ligands with selectivity for HIF-expressing osteosarcoma and renal cancer cell lines

A series of naphthalene derivatives with disubstituted triazole side-arms have been assembled by click chemistry. Lead compounds show a high level of selectivity for renal, osteo- and Ewing's sarcomas that express the HIF-1α transcription factor. They also interact selectively with the quadruplex DNAs located in the promoter of the HIF genes and it is suggested that the mechanism of action involves inhibition of transcription by drug-mediated quadruplex stabilization in these regions.

Relations between physical-chemical properties, chemical reactivity and local anesthetic effect in some procaine analogues. (Change of the carboxyl-group). 26

-